08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

GFT505: Phase II data

In the 28-day, double-blind, international Phase IIa GFT505-2083 trial in 97 pre-diabetics with atherogenic dyslipidemia and abdominal obesity, 80 mg/day oral GFT505 met the co-primary endpoints and multiple secondary endpoints. On the co-primary endpoints, GFT505...
08:00 , Dec 18, 2008 |  BC Innovations  |  Distillery Techniques

This week in techniques

The Distillery: Techniques Approach Summary Licensing status Publication and contact information Markers Assessment of pulmonary arterial hypertension...